Quanterix (NASDAQ:QTRX) Announces Earnings Results, Misses Estimates By $0.63 EPS

Posted by Geri Gentry on Aug 11th, 2026

Quanterix (NASDAQ:QTRX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.63), FiscalAI reports. The business had revenue of $32.91 million for the quarter, compared to analysts’ expectations of $37.46 million. Quanterix had a negative return on equity of 23.92% and a negative net margin of 71.86%.

Here are the key takeaways from Quanterix’s conference call:

2026 revenue guidance was cut substantially to $142 million–$148 million from $169 million–$174 million, reflecting a broad-based Q2 shortfall, weak academic/government spending, market softness, and commercial execution issues.
Q3 revenue is expected to be flat to slightly above Q2, while cash-flow breakeven has been delayed to 2027; the company expects double-digit cash usage in Q3 and approximately $80 million of cash at year-end, versus roughly $100 million previously.
Quanterix is reorganizing its commercial operation around solution-based selling and adding experienced leaders, including Jim Gute as chief commercial officer, to improve sales productivity across Simoa, Spatial, and Accelerator.
The company reported encouraging indicators, including sequentially higher bookings and a 1.0 book-to-bill ratio, sequential growth in pharma revenue, increased LucentAD Complete test volume, and new spatial and neurology assay launches.
Quanterix highlighted growing support for its Alzheimer’s diagnostics strategy: LucentAD Complete has CMS pricing of $897, gained Anthem coverage effective July 1 when medical-necessity criteria are met, and remains in productive FDA discussions with potential clearance expected toward year-end.

Quanterix Price Performance

QTRX opened at $2.42 on Tuesday. Quanterix has a 12 month low of $2.15 and a 12 month high of $8.77. The stock’s 50 day moving average price is $3.68 and its 200 day moving average price is $4.17. The stock has a market cap of $114.01 million, a P/E ratio of -1.03 and a beta of 1.07.

Institutional Trading of Quanterix

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in Quanterix during the fourth quarter valued at about $27,000. Quarry LP raised its position in Quanterix by 277,300.0% in the third quarter. Quarry LP now owns 5,548 shares of the company’s stock worth $30,000 after acquiring an additional 5,546 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Quanterix in the 4th quarter valued at about $75,000. HUB Investment Partners LLC acquired a new stake in Quanterix in the 2nd quarter valued at about $81,000. Finally, HRT Financial LP bought a new position in shares of Quanterix during the 4th quarter valued at about $82,000. Institutional investors own 86.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on QTRX shares. TD Cowen dropped their price target on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating for the company in a research note on Thursday, May 7th. Weiss Ratings downgraded shares of Quanterix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Canaccord Genuity Group dropped their target price on shares of Quanterix from $8.00 to $4.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Quanterix has a consensus rating of “Reduce” and an average target price of $4.00.

View Our Latest Analysis on Quanterix

Quanterix Company Profile

(Get Free Report)

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.